Value AD
CAN BE
ALTERNATIVE
INVESTMENT
NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
PAR-24-049
National Institutes of Health
Funding Opportunity Number: PAR-24-049
Opportunity Category: Discretionary
CFDA Number(s): 93.233 -- National Center on Sleep Disorders Research,93.837 -- Cardiovascular Diseases Research,93.838 -- Lung Diseases Research,93.839 -- Blood Diseases and Resources Research,93.840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Cost Sharing or Matching Requirement: No
Posted Date: Nov 03, 2023 12:00:00 AM EDT
Closing Date: Jan 07, 2027 12:00:00 AM EST
Award Ceiling: none
Award Floor: none
Eligible Applicants: City or township governments,Special district governments,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Others (see text field entitled "Additional Information on Eligibility" for clarification),State governments,Native American tribal governments (Federally recognized),Small businesses,Independent school districts,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,County governments,Public housing authorities/Indian housing authorities,For profit organizations other than small businesses,Public and State controlled institutions of higher education,Private institutions of higher education,Native American tribal organizations (other than Federally recognized tribal governments)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Agency Name: National Institutes of Health
Description: This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.
Grantor Contact Information: NIH Grants Information grantsinfo@nih.gov
